Search Within

Michael Morris

Formats
  1. Meeting Abstract (276)
  2. Journal Article (268)
  3. Review (21)
  4. Book Section (6)
  5. Editorial (6)
  6. Correspondence (4)
  7. Guidelines (3)
  8. Miscellaneous (2)
  9. Conference Paper (1)
  10. Research Letter (1)
Groups
  1. Department of Medicine (588)
  2. Genitourinary Oncology Service (588)
  3. Solid Tumor Oncology Division (588)
  4. Radiology, Department of (165)
  5. GSK Faculty (161)
  6. Molecular Imaging and Therapy Service (142)

More Groups

People
  1. Howard Scher (217)
  2. Steven Larson (93)
  3. Susan Slovin (90)
  4. Dana Rathkopf (79)
  5. Daniel Danila (54)
  6. Glenn Heller (54)

More People

Years
  1. 2025 (29)
  2. 2024 (50)
  3. 2023 (40)
  4. 2022 (50)
  5. 2021 (42)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (240)
  2. Journal of Nuclear Medicine (45)
  3. Clinical Cancer Research (33)
  4. Annals of Oncology (30)
  5. Cancer (18)
  6. European Urology (18)

More Publications

Publishers
  1. American Society of Clinical Oncology (250)
  2. Society of Nuclear Medicine (45)
  3. American Association for Cancer Research (43)
  4. Oxford University Press (41)
  5. Elsevier Science, Inc. (40)
  6. Elsevier Inc. (27)

More Publishers

Results (588)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B)
    Meeting Abstract

    Ryan, C. J.; Dutta, S.; Kelly, W.; Morris, M. J.; Taplin, M. E.; Halabi, S.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Morris, M. J.; Vogelzang, N. J.; Sartor, O.; Armour, A.; Messmann, R.; Groaning, M.; Robarts, A.; Tolcher, A. W.; Gordon, M.; Babiker, H. M.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials
    Meeting Abstract

    Choueiri, T. K.; Flaifel, A.; Xie, W.; Braun, D.; Ficial, M.; Jennings, R.; Nassar, A.; Escudier, B.; George, D. J.; Motzer, R. J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Halabi, S.; Dutta, S.; Tangen, C. M.; Rosenthal, M.; Petrylak, D. P.; Thompson, I. M.; Chi, K. N.; De Bono, J. S.; Fandi, A.; Araujo, J. C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs
    Meeting Abstract

    Morris, M. J.; Vogelzang, N. J.; Sartor, A. O.; Armour, A. A.; Messmann, R. A.; Groaning, M.; Robarts, A.; Tolcher, A. W.; Gordon, M. S.; Babiker, H. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial
    Meeting Abstract

    George, D. J.; Hessel, C.; Halabi, S.; Sanford, B. L.; Michaelson, M. D.; Hahn, O. M.; Walsh, M. K.; Olencki, T.; Picus, J.; Small, E. J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Management of biochemically recurrent prostate cancer: Ensuring the right treatment of the right patient at the right time
    Journal Article

    Spratt, D. E.; McHugh, D. J.; Morris, M. J.; Morgans, A. K.
    American Society of Clinical Oncology Educational Book (2018)

    Fulltext@MSK | Save
  • Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: A phase 2 clinical trial
    Journal Article

    Autio, K. A.; Dreicer, R.; Anderson, J.; Garcia, J. A.; Alva, A.; Hart, L. L.; Milowsky, M. I.; Posadas, E. M.; Ryan, C. J.; Graf, R. P.; more...
    JAMA Oncology (2018)

    Fulltext@MSK | Save
  • Reproducibility and repeatability of semiquantitative (18)F-fluorodihydrotestosterone uptake metrics in castration-resistant prostate cancer metastases: A prospective multicenter study
    Journal Article

    Vargas, H. A.; Kramer, G. M.; Scott, A. M.; Weickhardt, A.; Meier, A. A.; Parada, N.; Beattie, B. J.; Humm, J. L.; Staton, K. D.; Zanzonico, P. B.; more...
    Journal of Nuclear Medicine (2018)

    Fulltext@MSK | Save
  • The comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: A study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CD
    Journal Article

    Pacyna, J. E.; Kim, S.; Yost, K.; Sedlacek, H.; Petereit, D.; Kaur, J.; Rapkin, B.; Grubb, R.; Paskett, E.; Chang, G. J.; more...
    BMC Cancer (2018)

    Fulltext@MSK | Save